REFERENCES
1. National Center for Biotechnology Information. Spinal muscular atrophy; 1998. Available from: https://www.ncbi.nlm.nih.gov/books/NBK22213/ [Last accessed on 22 Sep 2025].
2. Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24:11939.
3. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12:124.
4. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155-65.
5. Prior TW, Leach ME, Finanger EL. Spinal muscular atrophy; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1352/ [Last accessed on 22 Sep 2025].
6. Butchbach ME. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci. 2016;3:7.
7. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3:49-51.
9. Prior TW, Leach ME, Finanger EL. Spinal muscular atrophy, type II. Available from: https://www.ncbi.nlm.nih.gov/medgen/95975 [Last accessed on 22 Sep 2025].
10. Salort-Campana E, Quijano-Roy S. Clinical features of spinal muscular atrophy (SMA) type 3 (Kugelberg-Welander disease). Arch Pediatr. 2020;27:7S23-8.
11. Wijngaarde CA, Stam M, Otto LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95:e1988-98.
12. Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24:529-33.
13. Calder AN, Androphy EJ, Hodgetts KJ. Small molecules in development for the treatment of spinal muscular atrophy. J Med Chem. 2016;59:10067-83.
14. Dhuri K, Bechtold C, Quijano E, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020;9:2004.
15. Bowerman M, Becker CG, Yáñez-Muñoz RJ, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech. 2017;10:943-54.
16. Singh RN, Singh NN. Mechanism of splicing regulation of spinal muscular atrophy genes. In: Sattler R, Donnelly CJ, editors. RNA Metabolism in Neurodegenerative Diseases. Cham: Springer International Publishing; 2018. pp. 31-61.
17. Bruce A, Alexander J, Julian L, Martin R, Keith R, Peter W. Proteins are made on polyribosomes; 2002. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26829/ [Last accessed on 22 Sep 2025].
18. Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 2001;20:3617-22.
19. Wise JA, Lou H. Transcription | messenger RNA processing in eukaryotes. Encyclopedia of Biological Chemistry III. Elsevier; 2021. pp. 411-9.
20. Lodish HF. Molecular cell biology, 6th ed. United States: W.H. Freeman; 2008. Available from: https://books.google.com/books/about/Molecular_Cell_Biology.html?id=K3JbjG1JiUMC [Last accessed on 24 Sep 2025].
21. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701-18.
22. McManus CJ, Graveley BR. RNA structure and the mechanisms of alternative splicing. Curr Opin Genet Dev. 2011;21:373-9.
23. Pellizzoni L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep. 2007;8:340-5.
24. Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and victor's principles of neurology, 11e. McGraw-Hill Education; 2019. Available from: https://neurology.mhmedical.com/content.aspx?bookid=1477§ionid=215135193 [Last accessed on 24 Sep 2025].
25. Hassan HA, Zaki MS, Issa MY, El-Bagoury NM, Essawi ML. Genetic pattern of SMN1, SMN2, and NAIP genes in prognosis of SMA patients. Egypt J Med Hum Genet. 2020;21:44.
26. Kernochan LE, Russo ML, Woodling NS, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet. 2005;14:1171-82.
27. Cao YY, Qu YJ, He SX, et al. Association between SMN2 methylation and disease severity in Chinese children with spinal muscular atrophy. J Zhejiang Univ Sci B. 2016;17:76-82.
28. Narcís JO, Tapia O, Tarabal O, et al. Accumulation of poly(A) RNA in nuclear granules enriched in Sam68 in motor neurons from the SMNΔ7 mouse model of SMA. Sci Rep. 2018;8:9646.
29. Eperon IC, Makarova OV, Mayeda A, et al. Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol Cell Biol. 2000;20:8303-18.
30. Xue J, Ma T, Zhang X. TRA2: the dominant power of alternative splicing in tumors. Heliyon. 2023;9:e15516.
31. Singh NN, Lee BM, DiDonato CJ, Singh RN. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem. 2015;7:1793-808.
32. Förch P, Puig O, Martínez C, Séraphin B, Valcárcel J. The splicing regulator TIA-1 interacts with U1-C to promote U1 snRNP recruitment to 5' splice sites. EMBO J. 2002;21:6882-92.
33. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci. 2000;25:106-10.
34. Goren A, Ram O, Amit M, et al. Comparative analysis identifies exonic splicing regulatory sequences-The complex definition of enhancers and silencers. Mol Cell. 2006;22:769-81.
35. Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi K. An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J Biol Chem. 2003;278:15825-31.
36. Han J, Ding JH, Byeon CW, et al. SR proteins induce alternative exon skipping through their activities on the flanking constitutive exons. Mol Cell Biol. 2011;31:793-802.
37. Kashima T, Rao N, David CJ, Manley JL. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet. 2007;16:3149-59.
38. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem. 2002;277:23271-7.
39. Passmore LA, Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2022;23:93-106.
40. Li Q. Nusinersen as a therapeutic agent for spinal muscular atrophy. Yonsei Med J. 2020;61:273-83.
42. U.S. Food and Drug Administration. SPINRAZA (Nusinersen) injection, for intrathecal use: highlights of prescribing information; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf [Last accessed on 22 Sep 2025].
43. Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24:194-203.
44. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723-32.
45. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625-35.
46. Ratni H, Scalco RS, Stephan AH. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med Chem Lett. 2021;12:874-7.
47. Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915-23.
48. Sturm S, Günther A, Jaber B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85:181-93.
49. Masson R, Mazurkiewicz-Bełdzińska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21:1110-9.
50. Oskoui M, Day JW, Deconinck N, et al. Correction to: Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270:2547-9.
51. Cheung AK, Hurley B, Kerrigan R, et al. Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61:11021-36.
52. Keller CG, Shin Y, Monteys AM, et al. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun. 2022;13:1150.
53. Theil D, Kuhle J, Brees D, et al. Neurofilament light chain: a translational safety biomarker for drug-induced peripheral neurotoxicity. Toxicol Pathol. 2023;51:135-47.
54. Yeo CJJ, Darras BT. Overturning the Paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12-9.
55. Haque US, Yokota T. Recent progress in gene-targeting therapies for spinal muscular atrophy: promises and challenges. Genes. 2024;15:999.
56. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284-93.
57. Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832-41.
58. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28:1390-7.
59. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834-41.
60. Muntoni F, Bertini E, Comi G, et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul Disord. 2020;30:959-69.
61. Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:513-22.
62. Villanova M, Bach JR. Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. Am J Phys Med Rehabil. 2015;94:410-5.
63. Mirea A, Shelby ES, Axente M, et al. Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I. J Clin Med. 2021;10:5540.
64. Zhang W, Yin Y, Yang D, et al. Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database. Front Pharmacol. 2024;15:1475884.
65. Waldrop MA, Karingada C, Storey MA, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146:e20200729.
66. Kotulska K, Jozwiak S, Jedrzejowska M, et al. Newborn screening and gene therapy in SMA: challenges related to vaccinations. Front Neurol. 2022;13:890860.
67. Sleigh JN, Gillingwater TH, Talbot K. The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech. 2011;4:457-67.
68. Kray KM, McGovern VL, Chugh D, Arnold WD, Burghes AHM. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice. Neurobiol Dis. 2021;159:105488.
69. Zhao X, Feng Z, Ling KK, et al. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy. Hum Mol Genet. 2016;25:1885-99.
70. Seo J, Singh NN, Ottesen EW, Sivanesan S, Shishimorova M, Singh RN. Oxidative stress triggers body-wide skipping of multiple exons of the spinal muscular atrophy gene. PLoS One. 2016;11:e0154390.
71. Baenas N, Wagner AE. Drosophila melanogaster as an alternative model organism in nutrigenomics. Genes Nutr. 2019;14:14.
72. Praveen K, Wen Y, Matera AG. A Drosophila model of spinal muscular atrophy uncouples snRNP biogenesis functions of survival motor neuron from locomotion and viability defects. Cell Rep. 2012;1:624-31.
73. Spring AM, Raimer AC, Hamilton CD, Schillinger MJ, Matera AG. Comprehensive modeling of spinal muscular atrophy in drosophila melanogaster. Front Mol Neurosci. 2019;12:113.
74. Gonzalez D, Vásquez-Doorman C, Luna A, Allende ML. Modeling spinal muscular atrophy in zebrafish: current advances and future perspectives. Int J Mol Sci. 2024;25:1962.
75. McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919-31.
76. Cerneckis J, Cai H, Shi Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduct Target Ther. 2024;9:112.
77. Bautista CM, Sterneckert J. Progress and challenges in directing the differentiation of human iPSCs into spinal motor neurons. Front Cell Dev Biol. 2022;10:1089970.
78. Pagliari E, Taiana M, Manzini P, et al. Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models. Cell Mol Life Sci. 2024;82:29.
79. Ohuchi K, Funato M, Kato Z, et al. Established stem cell model of spinal muscular atrophy is applicable in the evaluation of the efficacy of thyrotropin-releasing hormone analog. Stem Cells Transl Med. 2016;5:152-63.
80. Wang J, Schultz PG, Johnson KA. Mechanistic studies of a small-molecule modulator of SMN2 splicing. Proc Natl Acad Sci USA. 2018;115:E4604-12.
81. Zheleznyakova GY, Voisin S, Kiselev AV, et al. Genome-wide analysis shows association of epigenetic changes in regulators of Rab and Rho GTPases with spinal muscular atrophy severity. Eur J Hum Genet. 2013;21:988-93.
82. Zwartkruis MM, Kortooms JV, Gommers D, et al. Comprehensive analysis across SMN2 excludes DNA methylation as an epigenetic biomarker for spinal muscular atrophy. iScience. 2025;28:112461.
83. Redman M, King A, Watson C, King D. What is CRISPR/Cas9? Arch Dis Child Educ Pract Ed. 2016;101:213-5.
84. Li JJ, Lin X, Tang C, et al. Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice. Natl Sci Rev. 2020;7:92-101.
85. Kariyawasam DST, D'Silva A, Lin C, Ryan MM, Farrar MA. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol. 2019;10:898.
86. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10:597-609.
87. Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6:932-44.
88. Virata MCA, Catahay JA, Lippi G, Henry BM. Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. Neurodegener Dis Manag. 2024;14:227-39.
89. Rutkove SB, Gregas MC, Darras BT. Electrical impedance myography in spinal muscular atrophy: a longitudinal study. Muscle Nerve. 2012;45:642-7.
90. Huang Y, Chen T, Hu Y, Li Z. Muscular MRI and magnetic resonance neurography in spinal muscular atrophy. Clin Radiol. 2024;79:673-80.
91. Glanzman AM, Mazzone E, Main M, et al. The children's hospital of philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155-61.
92. Nelson LL, Iannaccone ST. Clinical outcome assessments in Duchenne muscular dystrophy and spinal muscular atrophy: past, present and future. Neuromuscul Disord. 2021;31:1028-37.
93. Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological exam-part 2: experience from a nusinersen clinical study. Muscle Nerve. 2018;57:142-6.
94. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155-9.
95. Ramsey D, Scoto M, Mayhew A, et al. Revised hammersmith scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. PLoS One. 2017;12:e0172346.
96. Wolfe A, Stimpson G, Ramsey D, et al. Disease trajectories in the revised hammersmith scale in a cohort of untreated patients with spinal muscular atrophy types 2 and 3. J Neuromuscul Dis. 2024;11:665-77.
97. Krosschell KJ, Scott CB, Maczulski JA, Lewelt AJ, Reyna SP, Swoboda KJ; Project Cure SMA. Reliability of the modified hammersmith functional motor scale in young children with spinal muscular atrophy. Muscle Nerve. 2011;44:246-51.
98. Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol. 2022;39:1-10.
99. Motyl AAL, Faller KME, Groen EJN, et al. Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy. Hum Mol Genet. 2020;29:2674-83.
100. Hatanaka F, Suzuki K, Shojima K, et al. Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing. Nat Commun. 2024;15:6191.
101. Nguyen TT, Dung Nguyen TT, Vo TK, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021;143:112117.
